Shire’s Fosrenol User Fee Date Is Oct. 26 Following 90-Day Extension

FDA extends the review timeline to evaluate recently submitted dosage strength and formulation data. Shire says no clinical or safety concerns have been raised and market preparation for a late 2004 launch is proceeding as planned.